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The inherited periodic fever syndromes are single gene
disorders of innate immunity which have provided
invaluable insights into the regulation of inflammation.
They are all extremely rare but are clinically important as
they cause very significant day to day symptoms and
carry a high risk of early death due to AA amyloidosis.
With the exception of familial Mediterranean fever treat-
ment was essentially ineffective until this century.
The discovery in 2002 that specific IL-1 blockade com-
pletely prevented all symptoms in cryopyrin associated
periodic syndrome (CAPS) transformed treatment of this
rare genetic disease. Isolation of the responsible gene,
NLRP3, followed by rapid advances in molecular biology
and identification of the inflammasome has made it clear
that CAPS is purely a disease of IL-1 dysregulation. These
discoveries combined with the availability of specific anti
IL-1 agents have resulted in new insights into the regula-
tion of IL-1 beta production in humans and its long term
consequences.
IL-1 is now recognised to be an important mediator of
inflammation in other inherited autoinflammatory diseases
such as Familial Mediterranean fever (FMF), TNF receptor
associated periodic syndrome (TRAPS), deficiency of IL-1
receptor antagonist (DIRA) and mevalonate kinase defi-
ciency and has transformed patient prognosis and quality
of life. In addition the recognition that IL-1 blockade pro-
vides complete disease control in acquired diseases of
uncertain aetiology particularly Schnitzler’s syndrome and
systemic onset juvenile chronic arthritis (SoJIA), adult
onset Stills disease and recurrent idiopathic pericarditis
has made it clear that these too are autoinflammatory dis-
orders. One of the most striking features of these diseases
is that IL-1 blocking agents have been used for prolonged
periods as monotherapy without serious side effects or
breakthrough of inflammatory activity thus differentiating
them from the commoner autoimmune disorders such as
rheumatoid arthritis and vasculitis.
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